COLL Collegium Pharmaceutical Inc.

Collegium to Present at Upcoming Investor Conferences

Collegium to Present at Upcoming Investor Conferences

STOUGHTON, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative and differentiated products for people suffering from pain, today announced that management will present at the following investor conferences in November:

  • The Jefferies Healthcare Conference on Wednesday, November 14th at 4:00 p.m. GMT in London
  • The Piper Jaffray Healthcare Conference on Tuesday, November 27th at 2:30 p.m. EST in New York City

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative and differentiated products for people suffering from pain and our communities. 

About Xtampza ER

Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Contact:

Alex Dasalla

EN
12/11/2018

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

 PRESS RELEASE
Free
COLL Collegium Pharm...

Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pha...

Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pharmaceutical BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- today announced a multi-year partnership with , an emerging biopharmaceutical leader in the Boston area, naming the company an Official Partner of Boston Legacy FC. Through this collaboration, Boston Legacy FC and Collegium are working together to ensure that the club’s home games are welcoming and sensory-inclusive for all fans. As part of the partnership, the Collegium Sensory Room will be available at Gillette Stadium and Centreville Bank Stadium in 2026, and Wh...

February 23, 2026 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report Fourth Quarter and Full-Year 2025 Financial Result...

Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026 STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q4 ...

February 12, 2026 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Present Four Real-World Data Posters at APSARD 2026 Annua...

Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product, Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older and developed using a novel delayed-release extended-release delivery platform, at the American Professional Society of ADHD and Related Disorders (A...

January 15, 2026 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Provides 2026 Financial Guidance and Business Update

Collegium Provides 2026 Financial Guidance and Business Update – Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million – STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced its 2026 full-year financial guidance and provided a business update. “2025 was a year of record growth for Collegium and we are excited to begin 2026 with significant momentum ...

January 8, 2026 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Announces the Closing of $980 Million Syndicated Credit Faci...

Collegium Announces the Closing of $980 Million Syndicated Credit Facility Five-Year Financing with Favorable Terms that Significantly Reduce Interest Rate STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility. The new aggregate $980 million credit facility will mature in 2030 and consists of a $580 million initial Term Loan, $300 million Delayed Draw Term Loan, and $100 million revolving credit facility (collectively the “Credit Facility”). The initial Term Loan was used...

December 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch